This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Bionomics Past Earnings Performance
Past criteria checks 0/6
Bionomics's earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been declining at an average rate of 42.6% per year.
Key information
-3.43%
Earnings growth rate
27.76%
EPS growth rate
Biotechs Industry Growth
-14.59%
Revenue growth rate
-42.62%
Return on equity
-52.21%
Net Margin
-413.94%
Last Earnings Update
31 Dec 2022
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bionomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:B1N Revenue, expenses and earnings (AUD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 22
6
-25
7
0
30 Sep 22
6
-23
7
0
30 Jun 22
6
-22
8
0
31 Mar 22
3
-22
8
0
31 Dec 21
0
-22
8
0
30 Sep 21
1
-15
7
0
30 Jun 21
1
-9
6
0
31 Mar 21
1
-4
5
0
31 Dec 20
2
1
5
0
30 Sep 20
2
-3
5
0
30 Jun 20
3
-6
5
0
31 Dec 19
6
-5
5
0
30 Sep 19
7
-8
6
0
30 Jun 19
7
-10
8
0
31 Mar 19
8
-20
11
0
31 Dec 18
8
-28
11
0
30 Sep 18
10
-27
11
0
30 Jun 18
12
-25
11
0
31 Mar 18
19
-15
9
0
31 Dec 17
27
-6
8
0
30 Sep 17
27
-6
8
0
30 Jun 17
27
-7
8
0
31 Mar 17
22
-12
10
0
31 Dec 16
16
-17
12
0
30 Sep 16
18
-17
11
0
30 Jun 16
19
-17
11
0
31 Mar 16
19
-19
10
0
31 Dec 15
18
-21
9
0
30 Sep 15
17
-19
9
0
30 Jun 15
15
-17
9
0
31 Mar 15
22
-6
7
0
31 Dec 14
29
4
5
0
30 Sep 14
28
4
5
0
30 Jun 14
27
3
5
0
31 Mar 14
19
-5
5
0
31 Dec 13
12
-13
5
0
30 Sep 13
12
-11
5
0
30 Jun 13
12
-10
5
0
31 Mar 13
13
-7
5
0
31 Dec 12
13
-4
4
0
30 Sep 12
12
-3
4
0
Quality Earnings: B1N is currently unprofitable.
Growing Profit Margin: B1N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B1N is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare B1N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B1N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Return on Equity
High ROE: B1N has a negative Return on Equity (-52.21%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/09/01 19:18
End of Day Share Price
2023/08/24 00:00
Earnings
2022/12/31
Annual Earnings
2022/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.